Metabolic syndrome in women with sheehan syndrome: prevalence and associated factors

Salma Salhi; Ibtissem Oueslati; Emna Talbi; Anis Grassa; Arige Abid; Meriem Yazid; Moncef Feki; Melika Chihaoui

doi:10.1530/endoabs.99.P112

P112

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 P112 | DOI: 10.1530/endoabs.99.P112

ECE2024 Poster Presentations Pituitary and Neuroendocrinology (120 abstracts)

Metabolic syndrome in women with sheehan syndrome: prevalence and associated factors

Salma Salhi ¹ , Ibtissem Oueslati ¹ , Emna Talbi ² , Anis Grassa ¹ , Arige Abid ¹ , Meriem Yazid ¹ , Moncef Feki ² & Melika Chihaoui ¹

Err

Author affiliations

¹La Rabta University Hospital, Department of Endocrinology, Tunis, Tunisia; ²La Rabta University Hospital, Laboratory of Biochemistry, Tunis, Tunisia

Introduction: Sheehan’s syndrome (SS) is characterized by a deficiency in pituitary hormone secretion. It is now being closely inspected for its implication in the onset of metabolic syndrome (MS). The aims of this study were to determine the prevalence of MS and assess its associated factors in women with SS.

Methods: We carried out a cross-sectional study involving 50 patients diagnosed with SS and 50 controls, matched for age and body-mass index (BMI). Waist circumference measurement, 24-hour ambulatory blood pressure monitoring, and laboratory tests were performed in all participants. MS was defined according to the IDF-2009 criteria.

Results: The average age was 62.2 ± 9.4 years in patients and 60.6 ± 8.4 years in controls (P=0.385). The mean BMI was 29.6 ± 6,0 kg/m² in patients vs 30.0 ± 5.0 kg/m² in controls (P=0, 741). Waist circumference was significantly higher in patients (101.3 ± 10.2 cm) than in controls (95.7 ± 10.5 cm) (P=0.007). It was ≥ 80 cm in 98% of patients and in 86% of controls (P=0.027). The prevalence of MS was 64% in patients and 40% in controls (P=0.016). Among these patients, 87% of women with SS and 100% of the CG had three to four MS criteria. The coexistence of all five MS criteria was observed only in patients (13%). SS was positively associated with MS (Odds Ratio=2.66,: 1.18-5.98, P=0.016). In women with SS, age, diagnostic delay, disease duration, GH levels, FT4 levels, daily dose of levothyroxine, daily and cumulative dose of hydrocortisone, and estroprogestative therapy were not associated with MS.

Conclusion: These results emphasize the need for monitoring and managing components of MS in individuals with SS. Clinicians should develop targeted interventions that can effectively mitigate the risk of MS and its associated complications in this specific population.